Education
About Us
Working with TipRanks
Follow Us
NeuroPace (NPCE)
NASDAQ:NPCE
NPCE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.45 - $15.77
Previous CloseN/A
Volume21.31K
Average Volume (3M)302.15K
Market Cap
$358.16M
Enterprise Value$221.90M
Total Cash (Recent Filing)$13.43M
Total Debt (Recent Filing)$73.34M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
May 08, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding32,560,130
10 Day Avg. Volume269,973
30 Day Avg. Volume302,147
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.68
Price to Cash Flow (P/CF)-49.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda-13.39
Forecast
1Y Price Target
$17.67Price Target Upside60.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
NeuroPace News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe NAUTILUS trial is on track to complete required follow-up, with an FDA submission expected, seen as a catalyst for growth.
Revenue GrowthNeuroPace reported final Q4’24 results of $21.5M, which was ahead of previous estimates.
Bears Say
Cash FlowQ4 cash burn increased to $4.8M compared to $3.4M in the previous year.
---
Ownership Overview
42.42% Insiders
5.40% Mutual Funds
17.78% Other Institutional Investors
22.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NPCE FAQ
What was NeuroPace’s price range in the past 12 months?
NeuroPace lowest stock price was $5.45 and its highest was $15.77 in the past 12 months.
What is NeuroPace’s market cap?
NeuroPace’s market cap is $358.16M.
When is NeuroPace’s upcoming earnings report date?
NeuroPace’s upcoming earnings report date is May 08, 2025 which is in 57 days.
How were NeuroPace’s earnings last quarter?
NeuroPace released its earnings results on Mar 04, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.043.
Is NeuroPace overvalued?
According to Wall Street analysts NeuroPace’s price is currently Undervalued.
Does NeuroPace pay dividends?
NeuroPace does not currently pay dividends.
What is NeuroPace’s EPS estimate?
NeuroPace’s EPS estimate is -0.24.
How many shares outstanding does NeuroPace have?
NeuroPace has 32,560,130 shares outstanding.
What happened to NeuroPace’s price movement after its last earnings report?
NeuroPace reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -2.433%.
Which hedge fund is a major shareholder of NeuroPace?
Currently, no hedge funds are holding shares in NPCE
---
NeuroPace Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.67 (60.64% Upside)
$17.67 (60.64% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 12.3%
Last 30 Days ▼ 12.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.15%
12-Months-Change
Fundamentals
Return on Equity
-189.35%
Trailing 12-Months
Asset Growth
-12.08%
Trailing 12-Months
Company Description
NeuroPace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
---
NPCE Company Deck
---
NPCE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
NeuroPace demonstrated strong revenue growth and operational success in 2024, with significant advancements in clinical trials and product development. Despite a net loss and increased operating expenses, the company's strategic initiatives, including Project CARE and successful public offering, position it well for future growth. The overall sentiment is positive, given the successful financial and operational achievements overshadowing the financial challenges.Read More>---
NPCE Stock 12 Month Forecast
Average Price Target
$17.67
▲(60.64% Upside)
Technical Analysis
Best Analysts Covering NPCE
1 Year
1 Year Success Rate
13/20 ratings generated profit
1 Year Average Return
+48.59%
reiterated a buy rating 8 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +48.59% per trade.
---